Avricore Health Inc. Files May 2024 6-K Report
Ticker: AVCRF · Form: 6-K · Filed: Jun 20, 2024 · CIK: 1355736
| Field | Detail |
|---|---|
| Company | Avricore Health INC. (AVCRF) |
| Form Type | 6-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, regulatory-filing
Related Tickers: AVCR
TL;DR
AVRICORE HEALTH (AVCR) filed its May 6-K report, standard foreign issuer update.
AI Summary
Avricore Health Inc. filed a Form 6-K on June 20, 2024, for the month ending May 31, 2024. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceuticals Inc., and ALDA Pharmaceuticals Corp., is headquartered in Vancouver, BC. This filing is a report of a foreign private issuer.
Why It Matters
This filing provides an update on Avricore Health Inc.'s activities and financial reporting as a foreign private issuer, which is important for investors tracking the company's regulatory compliance and operational status.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information that would inherently increase risk.
Key Players & Entities
- Avricore Health Inc. (company) — Registrant
- Vanc Pharmaceuticals Inc. (company) — Former company name
- NUVA Pharmaceuticals Inc. (company) — Former company name
- ALDA Pharmaceuticals Corp. (company) — Former company name
- 20240531 (date) — Reporting period end date
- 20240620 (date) — Filing date
FAQ
What is the primary purpose of a Form 6-K filing?
A Form 6-K filing is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company has made or is required to make public in its home country, or that it has distributed or made available to its security holders.
What is the reporting period covered by this Form 6-K?
This Form 6-K covers the month of May 2024, with the period of report ending on May 31, 2024.
What were Avricore Health Inc.'s previous names?
Avricore Health Inc. was formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceuticals Inc., and ALDA Pharmaceuticals Corp.
Where is Avricore Health Inc. headquartered?
Avricore Health Inc. is headquartered at 1120-789 West Pender St, Vancouver, BC, V6C 1H2.
Is Avricore Health Inc. filing its annual report on Form 20-F or 40-F?
Avricore Health Inc. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 19.7 · Accepted 2024-06-20 06:05:41
Filing Documents
- form6-k.htm (6-K) — 27KB
- ex1.htm (EX-1) — 520KB
- ex2.htm (EX-2) — 161KB
- ex3.htm (EX-3) — 12KB
- ex4.htm (EX-4) — 12KB
- ex5.htm (EX-5) — 2KB
- ex6.htm (EX-10) — 453KB
- ex7.htm (EX-7) — 2KB
- ex8.htm (EX-8) — 1KB
- ex9.htm (EX-9) — 2KB
- ex1_001.jpg (GRAPHIC) — 10KB
- ex2_001.jpg (GRAPHIC) — 14KB
- ex5_001.jpg (GRAPHIC) — 339KB
- ex5_002.jpg (GRAPHIC) — 273KB
- ex6_001.jpg (GRAPHIC) — 15KB
- ex7_001.jpg (GRAPHIC) — 300KB
- ex7_002.jpg (GRAPHIC) — 85KB
- ex8_001.jpg (GRAPHIC) — 218KB
- ex9_001.jpg (GRAPHIC) — 381KB
- ex9_002.jpg (GRAPHIC) — 283KB
- 0001493152-24-024386.txt ( ) — 3837KB
Financial Statements request form
Financial Statements request form 2024-05-30 9 Voting instruction form 2024-05-30
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AVRICORE HEALTH INC. Date: June 20, 2024 By “Kiki Smith” Kiki Smith Chief Financial Officer SEC1815(04-09) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number